Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2018

Open Access 01-12-2018 | Research article

H1-antihistamines are associated with lower prevalence of radiographic knee osteoarthritis: a cross-sectional analysis of the Osteoarthritis Initiative data

Authors: Ivan Shirinsky, Valery Shirinsky

Published in: Arthritis Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

There is growing evidence that mast cells (MCs) play a role in knee osteoarthritis (OA). H1-antihistamines block H1-receptors of histamine, which is an important mediator of MCs. There is a lack of data on whether H1-antihistamines can influence OA. We hypothesized that the use of H1-antihistamines may be linked to the reduced prevalence of knee OA.

Methods

Baseline data from the Osteoarthritis Initiative cohort were analysed cross-sectionally. Unadjusted and adjusted logistic regression models were performed to compare the prevalence of knee OA in H1-antihistamine users and non-users. Generalized estimating equations were used to adjust for the correlation between knees. Knee OA was defined as (1) Kellgren-Lawrence (KL) grade ≥ 2 or total joint replacement or (2) KL grade ≥ 2 and joint space narrowing or total joint replacement.

Results

The analysed sample consisted of 8545 knees (664 knees of H1-antihistamine users and 7881 knees of H1-antihistamine non-users). The use of H1-antihistamines was associated with reduced prevalence of knee OA in unadjusted and adjusted models using both the first (adjusted OR, 0.77; 95% CI, 0.62, 0.96; P < 0.02) and second (adjusted OR, 0.75; 95% CI, 0.62, 0.93; P < 0.008) definitions of knee OA.

Conclusions

H1-antihistamines are associated with a reduced prevalence of knee OA. The findings indicate that this class of drugs should be further evaluated for possible structure-modifying properties in knee OA.
Literature
1.
go back to reference Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Granata F. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.PubMedPubMedCentral Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Granata F. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.PubMedPubMedCentral
2.
go back to reference Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents. 2013;27(3):655–60.PubMed Kritas SK, Saggini A, Varvara G, Murmura G, Caraffa A, Antinolfi P, Toniato E, Pantalone A, Neri G, Frydas S, et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents. 2013;27(3):655–60.PubMed
3.
go back to reference Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardiometabolic diseases. Nat Rev Cardiol. 2015;12(11):643–58.CrossRefPubMed Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardiometabolic diseases. Nat Rev Cardiol. 2015;12(11):643–58.CrossRefPubMed
4.
go back to reference de Lange-Brokaar BJ, Kloppenburg M, Andersen SN, Dorjee AL, Yusuf E, Herb-van Toorn L, Kroon HM, Zuurmond AM, Stojanovic-Susulic V, Bloem JL, et al. Characterization of synovial mast cells in knee osteoarthritis: association with clinical parameters. Osteoarthritis Cartilage. 2016;24(4):664–71.CrossRefPubMed de Lange-Brokaar BJ, Kloppenburg M, Andersen SN, Dorjee AL, Yusuf E, Herb-van Toorn L, Kroon HM, Zuurmond AM, Stojanovic-Susulic V, Bloem JL, et al. Characterization of synovial mast cells in knee osteoarthritis: association with clinical parameters. Osteoarthritis Cartilage. 2016;24(4):664–71.CrossRefPubMed
5.
go back to reference Levi-Schaffer F, Eliashar R. Mast cell stabilizing properties of antihistamines. J Invest Dermatol. 2009;129(11):2549–51.CrossRefPubMed Levi-Schaffer F, Eliashar R. Mast cell stabilizing properties of antihistamines. J Invest Dermatol. 2009;129(11):2549–51.CrossRefPubMed
6.
go back to reference Driban JB, Lo GH, Eaton CB, Lapane KL, Nevitt M, Harvey WF, McCulloch CE, McAlindon TE. Exploratory analysis of osteoarthritis progression among medication users: data from the Osteoarthritis Initiative. Ther Adv Musculoskelet Dis. 2016;8(6):207–19.CrossRefPubMedPubMedCentral Driban JB, Lo GH, Eaton CB, Lapane KL, Nevitt M, Harvey WF, McCulloch CE, McAlindon TE. Exploratory analysis of osteoarthritis progression among medication users: data from the Osteoarthritis Initiative. Ther Adv Musculoskelet Dis. 2016;8(6):207–19.CrossRefPubMedPubMedCentral
8.
go back to reference Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994;10(4):405–11.CrossRefPubMed Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol. 1994;10(4):405–11.CrossRefPubMed
9.
10.
go back to reference Twisk J, de Vente W. Attrition in longitudinal studies: how to deal with missing data. J Clin Epidemiol. 2002;55(4):329–37.CrossRefPubMed Twisk J, de Vente W. Attrition in longitudinal studies: how to deal with missing data. J Clin Epidemiol. 2002;55(4):329–37.CrossRefPubMed
11.
go back to reference Dean G, Hoyland JA, Denton J, Donn RP, Freemont AJ. Mast cells in the synovium and synovial fluid in osteoarthritis. Br J Rheumatol. 1993;32(8):671–5.CrossRefPubMed Dean G, Hoyland JA, Denton J, Donn RP, Freemont AJ. Mast cells in the synovium and synovial fluid in osteoarthritis. Br J Rheumatol. 1993;32(8):671–5.CrossRefPubMed
12.
go back to reference Renoux M, Hilliquin P, Galoppin L, Florentin I, Menkes CJ. Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis. Osteoarthritis Cartilage. 1996;4(3):175–9.CrossRefPubMed Renoux M, Hilliquin P, Galoppin L, Florentin I, Menkes CJ. Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis--comparison with articular chondrocalcinosis and rheumatoid arthritis. Osteoarthritis Cartilage. 1996;4(3):175–9.CrossRefPubMed
13.
14.
go back to reference Tetlow LC, Woolley DE. Histamine stimulates the proliferation of human articular chondrocytes in vitro and is expressed by chondrocytes in osteoarthritic cartilage. Ann Rheum Dis. 2003;62(10):991–4.CrossRefPubMedPubMedCentral Tetlow LC, Woolley DE. Histamine stimulates the proliferation of human articular chondrocytes in vitro and is expressed by chondrocytes in osteoarthritic cartilage. Ann Rheum Dis. 2003;62(10):991–4.CrossRefPubMedPubMedCentral
15.
go back to reference Tetlow LC, Woolley DE. Histamine stimulates matrix metalloproteinase-3 and -13 production by human articular chondrocytes in vitro. Ann Rheum Dis. 2002;61(8):737–40.CrossRefPubMedPubMedCentral Tetlow LC, Woolley DE. Histamine stimulates matrix metalloproteinase-3 and -13 production by human articular chondrocytes in vitro. Ann Rheum Dis. 2002;61(8):737–40.CrossRefPubMedPubMedCentral
16.
go back to reference Facchini A, Borzi RM, Olivotto E, Platano D, Pagani S, Cetrullo S, Flamigni F. Role of polyamines in hypertrophy and terminal differentiation of osteoarthritic chondrocytes. Amino Acids. 2012;42(2–3):667–78.CrossRefPubMed Facchini A, Borzi RM, Olivotto E, Platano D, Pagani S, Cetrullo S, Flamigni F. Role of polyamines in hypertrophy and terminal differentiation of osteoarthritic chondrocytes. Amino Acids. 2012;42(2–3):667–78.CrossRefPubMed
17.
go back to reference Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem. 2005;280(10):9291–6.CrossRefPubMed Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem. 2005;280(10):9291–6.CrossRefPubMed
18.
go back to reference Zeng GQ, Chen AB, Li W, Song JH, Gao CY. High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis. Genet Mol Res. 2015;14(4):14811–22.CrossRefPubMed Zeng GQ, Chen AB, Li W, Song JH, Gao CY. High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis. Genet Mol Res. 2015;14(4):14811–22.CrossRefPubMed
19.
go back to reference Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A. 1994;91(9):3739–43.CrossRefPubMedPubMedCentral Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, Levi-Montalcini R. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A. 1994;91(9):3739–43.CrossRefPubMedPubMedCentral
20.
go back to reference Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8–17.CrossRefPubMed Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23(Suppl 1):S8–17.CrossRefPubMed
21.
go back to reference Sousa-Valente J, Calvo L, Vacca V, Simeoli R, Arevalo JC, Malcangio M. Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthritis Cartilage. 2018;26(1):84–94.CrossRefPubMed Sousa-Valente J, Calvo L, Vacca V, Simeoli R, Arevalo JC, Malcangio M. Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthritis Cartilage. 2018;26(1):84–94.CrossRefPubMed
22.
go back to reference Aquili A, Farinelli L, Bottegoni C, Antonicelli L, Gigante A. The effect of anti-IgE therapy in knee osteoarthritis: a pilot observational study. J Biol Regul Homeost Agents. 2017;31(4 Suppl 1):1–5.PubMed Aquili A, Farinelli L, Bottegoni C, Antonicelli L, Gigante A. The effect of anti-IgE therapy in knee osteoarthritis: a pilot observational study. J Biol Regul Homeost Agents. 2017;31(4 Suppl 1):1–5.PubMed
23.
go back to reference Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, Lebel B. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy. 2002;57(11):1067–70.CrossRefPubMed Carayol N, Crampette L, Mainprice B, Ben-Soussen P, Verrecchia M, Bousquet J, Lebel B. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy. 2002;57(11):1067–70.CrossRefPubMed
24.
go back to reference Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+−dependent protein kinase C, Raf/MEK/ERK and IKK/IκB/NF-κB signal cascades. Biochem Pharmacol. 2005;69(3):433–49.CrossRefPubMed Matsubara M, Tamura T, Ohmori K, Hasegawa K. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+−dependent protein kinase C, Raf/MEK/ERK and IKK/IκB/NF-κB signal cascades. Biochem Pharmacol. 2005;69(3):433–49.CrossRefPubMed
25.
go back to reference Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9(2):118–24.CrossRefPubMed Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9(2):118–24.CrossRefPubMed
26.
go back to reference Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol. 2000;30(12):3363–70.CrossRefPubMed Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol. 2000;30(12):3363–70.CrossRefPubMed
27.
go back to reference Shirinsky IV, Shirinsky VS. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol Int. 2014;34(5):613–6.CrossRefPubMed Shirinsky IV, Shirinsky VS. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol Int. 2014;34(5):613–6.CrossRefPubMed
28.
go back to reference Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefPubMed Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915–20.CrossRefPubMed
Metadata
Title
H1-antihistamines are associated with lower prevalence of radiographic knee osteoarthritis: a cross-sectional analysis of the Osteoarthritis Initiative data
Authors
Ivan Shirinsky
Valery Shirinsky
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2018
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-018-1619-7

Other articles of this Issue 1/2018

Arthritis Research & Therapy 1/2018 Go to the issue